We are live on ! Find out more

497 hedge funds and large institutions have $12.5B invested in Sanofi in 2014 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 188 increasing their positions, 153 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 38

30% more funds holding in top 10

Funds holding in top 10: 1013 (+3)

23% more repeat investments, than reductions

Existing positions increased: 188 | Existing positions reduced: 153

2% more funds holding

Funds holding: 487497 (+10)

9% more call options, than puts

Call options by funds: $66.9M | Put options by funds: $61.6M

3% more capital invested

Capital invested by funds: $12.1B → $12.5B (+$323M)

0.98% more ownership

Funds ownership: 17%17.98% (+0.98%)

Holders
497
Holders Change
+10
Holders Change %
+2.05%
% of All Funds
14.3%
Holding in Top 10
13
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+30%
% of All Funds
0.37%
New
54
Increased
188
Reduced
153
Closed
38
Calls
$66.9M
Puts
$61.6M
Net Calls
+$5.29M
Net Calls Change
-$275K

SNY Hedge Fund Activity: Q1 2014 in Review

497 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q1 2014, worth a combined $12.5B — up 2.7% from $12.1B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new SNY positions and 38 closed out — a net gain of 16 holders — while 188 added to existing stakes and 153 trimmed.

The largest buyer was Barrow, Hanley, Mewhinney & Strauss, adding an estimated $260M. The largest seller was UBS, cutting an estimated $158M.

  • 497 institutional investors held Sanofi (SNY) as of Q1 2014, up from 487 in Q4 2013.
  • Funds reported $12.5B of Sanofi stock for Q1 2014, up 2.7% quarter-over-quarter.
  • 54 funds opened new Sanofi positions in Q1 2014 and 38 closed out, a net change of +16 holders.
  • The largest Sanofi buyer in Q1 2014 was Barrow, Hanley, Mewhinney & Strauss, an estimated $260M added.
  • The largest Sanofi seller in Q1 2014 was UBS, an estimated $158M sold.

Based on aggregated 13F filings for Q1 2014.